Shots:

• Scripps Research to receive up front- development & commercialization milestones- option exercise fee and royalties on sales of new therapies and will conduct pre-clinical R&D activities and P-I studies (in some cases) while AbbVie get an exclusive option to further develop and commercialize therapies for cancer- immunology- neurology and fibrosis
• The collaboration marks the expansion of companies’ partnership signed in 2018- to develop T-cell therapies targeting solid tumors
• Additionally- Scripps Research will offer preclinical programs to AbbVie of mutual interest/yr. for consideration to be included in the collaboration. The companies will also work to advance CD3 bispecific against oncology targets selected by AbbVie

Click here to­ read full press release/ article | Ref: AbbVie | Image: AbbVie